Persist: Prospective Observational Cohort Study To Assess Persistence Of Inflectra(tm) (Infliximab) In Patients With Rheumatoid Diseases Who Are Either Naive To Biologics Or Switched From Stable Remicade(tm) (Infliximab)

Trial Profile

Persist: Prospective Observational Cohort Study To Assess Persistence Of Inflectra(tm) (Infliximab) In Patients With Rheumatoid Diseases Who Are Either Naive To Biologics Or Switched From Stable Remicade(tm) (Infliximab)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PERSIST
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jul 2017 Status changed from active, no longer recruiting to recruiting.
    • 23 May 2017 Planned primary completion date changed from 31 Jul 2018 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top